Home Newsfeeds Truist Securities Downgrades Aerie Pharmaceuticals to Hold

Truist Securities Downgrades Aerie Pharmaceuticals to Hold

Truist Securities analyst Gregory Fraser downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Hold.

byBenzinga Newsdesk

August 24, 2022

1 minute read

Truist Securities analyst Gregory Fraser downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Hold.

Movers
News

What’s Going On With Manchester United Stock?

By Adam Eckert

November 15, 9:48 AM

Manchester United Ltd (NYSE: MANU) shares are trading higher Wednesday after the company announced a management transition.

MANU

Scilex Holding Company Announces That Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms And Suspends Short-Sales Of Dividended Scilex Stock

By Benzinga Newsdesk

June 15, 9:05 AM

Scilex Holding Company (NASDAQ:SCLX, "Scilex")))), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC:SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing

SCLX

Scripps Approves New Contract For CEO Adam Symson

By Benzinga Newsdesk

August 2, 4:59 PM

The new agreement replaces a three-year contract that began Jan. 1, 2020. Symson assumed the president and CEO role in August 2017. Since that time, he has engineered the acquisition of ION Media and the

SSP

Precigen Regains Rights To CAR-T Platform For Hematological, Solid Tumor Indications

By Vandana Singh

April 4, 10:34 AM

Precigen Inc (NASDAQ:PGEN) amended its exclusive license agreement with Alaunos Therapeutics (previously known as Ziopharm Oncology Inc) to use the UltraCAR-T platform to develop…

PGEN

Truist Securities Downgrades Aerie Pharmaceuticals to Hold

Related Posts

What’s Going On With Manchester United Stock?

Scilex Holding Company Announces That Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms And Suspends Short-Sales Of Dividended Scilex Stock

Scripps Approves New Contract For CEO Adam Symson

Precigen Regains Rights To CAR-T Platform For Hematological, Solid Tumor Indications